ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,947.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction on Friday, April 12th. The shares were sold at an average price of $67.79, for a total value of $16,947.50. Following the transaction, the vice president now owns 59,731 shares in the company, valued at $4,049,164.49. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.04, for a total value of $14,010.00.

ANI Pharmaceuticals Stock Performance

ANIP opened at $65.48 on Thursday. The firm has a market cap of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $64.60 and a 200-day simple moving average of $58.52. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million during the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ANIP. Capital One Financial began coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target on the stock. Guggenheim lifted their price target on ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Truist Financial lifted their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright lifted their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $80.00.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Rubric Capital Management LP boosted its position in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after buying an additional 277,989 shares during the period. Invesco Ltd. boosted its position in shares of ANI Pharmaceuticals by 185.4% in the third quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after buying an additional 220,690 shares during the period. BlackRock Inc. boosted its position in shares of ANI Pharmaceuticals by 9.9% in the second quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock worth $114,825,000 after buying an additional 191,402 shares during the period. Vanguard Group Inc. boosted its position in shares of ANI Pharmaceuticals by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock worth $71,074,000 after buying an additional 156,594 shares during the period. Finally, Balyasny Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the third quarter worth $4,466,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.